Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...
Главные авторы: | Unnikrishnan, A, Deshpande, NP, Verma, A, Kumari, A, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
Cell Press
2017
|
Схожие документы
-
Myelodysplastic syndromes: moving towards personalized management
по: Eva Hellström-Lindberg, и др.
Опубликовано: (2020-07-01) -
Spliceosome mutations: 1 plus 1 does not always equal 2
по: Pellagatti, A, и др.
Опубликовано: (2020) -
Reduced translation of GATA1 in Diamond-Blackfan anemia.
по: Boultwood, J, и др.
Опубликовано: (2014) -
SF3B1 mutant myelodysplastic syndrome: Recent advances
по: Pellagatti, A, и др.
Опубликовано: (2020) -
Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
по: Pellagatti, A, и др.
Опубликовано: (2016)